Phenserine

DB04892InvestigationalSmall molecule

Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD.... Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD.

Mechanism: Phenserine is a highly selective, reversible acetylcholinesterase inhibitor, a mechanism of action known to improve memory and cognition in Alzheimer’s subjects. Phenserine may prove to concentrate in the brain rapidly which would reduce the incidence of drug toxicity and side effects.
Curator reviewed
Primary indication: For the treatment of Alzheimer's disease (AD).Curator reviewed
Formula / weight: C₂₀H₂₃N₃O₂ · 337.4155 g/mol (avg)

Resolves to

Compound

UNIISUE285UG3SCAS101246-66-6ChEMBLCHEMBL74926PubChem192706

Structure

InChIKeyPBHFNBQPZCRWQP-QUCCMNQESA-NSMILES[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC3=CC=CC=C3)=C1)N2C

Targets

P22303ACHEP06276BCHEP05067APP

What you can answer from here — as of April 02, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

292Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Phenserine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account